INTRODUCTION {#Sec1}
============

Pulmonary arterial hypertension (PAH) is a progressive disease with poor prognosis. It is generally characterized by constriction of pulmonary arteries and vascular remodeling. Right ventricular afterload (right ventricular hypertrophy and enlargement) is increased because of elevated pulmonary arterial pressure and pulmonary vascular resistance, which ultimately leads to right cardiac failure and death \[[@CR1]\]. Subjective symptoms of PAH include exertional dyspnea, fatigability, palpitations, chest pain, and syncope \[[@CR2]\].

Although the underlying mechanisms of PAH are not fully understood, vascular endothelial abnormalities cause an imbalance between vasoconstricting and vasodilating factors. In this situation, vasoconstricting factors exert a greater influence and increase shear stress. It is generally thought that remodeling of the pulmonary arterial media and narrowing of the pulmonary intravascular lumens due to increased cell proliferation are responsible for this imbalance \[[@CR3]--[@CR5]\].

Prostacyclin (PGI~2~) agents with various modes of action, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors are available for the treatment of PAH. Oral administration of any of these drugs is recommended for patients with PAH of World Health Organization (WHO) functional Class III or lower. For patients with Class IV PAH, continuous intravenous administration of PGI~2~ is recommended. Concomitant treatment with several drugs having different modes of action is recommended if the clinical response to monotherapy is inadequate \[[@CR6]--[@CR8]\].

PGI~2~ is a metabolite of arachidonic acid and plays an important role in maintaining pulmonary vascular homeostasis. It is produced by endocapillary cells, and acts as a potent vasodilator and inhibits platelet aggregation. Accordingly, the PGI~2~ system plays an important role in the inhibition of vascular smooth muscle cell proliferation and helps to protect the vascular endothelium. A small decline in the function of the PGI~2~ system leads to an imbalance between vasoconstrictors and vasodilators, and appears to contribute to the development of PAH \[[@CR9]--[@CR11]\].

Based on these findings, compounds that target prostacyclin receptors have been developed and are used clinically to treat PAH. One such example is intravenous epoprostenol sodium, a synthetic PGI~2~ analog, which is prepared as a formulation containing glycine and mannitol as excipients (epoprostenol GM, GlaxoSmithKline, London, UK). Continuous intravenous therapy with epoprostenol GM was reported to improve pulmonary hemodynamic factors, exercise tolerance, and the prognosis of PAH \[[@CR12]\]. However, one limitation of this formulation is that the prepared solution is thermally unstable, and needs to be administered within 8 h at room temperature (1--30 °C) or within 24 h if cooled to 2--8 °C using frozen gel packs. Consequently, the medication cassette containing the solution has to be maintained at 2--8 °C using a frozen gel pack for the entire 24-h infusion period \[[@CR13]\].

To overcome this limitation, another formulation of epoprostenol sodium, containing arginine and sucrose as excipients (Actelion Pharmaceuticals Japan Ltd., Tokyo, Japan; hereafter, epoprostenol AS), was developed to improve the convenience of using epoprostenol to treat PAH as the new formulation is stable for 24 h at room temperature \[[@CR14]\].

To date, however, few studies have examined the safety, potential effects on hemodynamic factors, or treatment satisfaction associated with switching formulations of epoprostenol in patients with PAH \[[@CR15]\]. Therefore, the authors performed a 12-week, open-label, Phase 3b study to examine the safety, efficacy, and treatment satisfaction of switching from epoprostenol GM to epoprostenol AS in Japanese patients with PAH. The authors hypothesized that switching from epoprostenol GM to epoprostenol AS would improve treatment satisfaction without increasing the incidence of adverse events or causing deteriorations in pulmonary hemodynamic factors.

METHODS {#Sec2}
=======

Ethics {#Sec3}
------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

Subjects {#Sec4}
--------

Patients aged ≥20 years at the time of informed consent and who had pulmonary hypertension classified as Group 1 using the Dana Point classification \[[@CR16],[@CR17]\] for pulmonary hypertension were eligible if they had any of the following: idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary arterial hypertension (HPAH), PAH associated with drugs and toxins, or PAH associated with connective tissue disease. Only patients who had been treated with epoprostenol GM for ≥3 months before enrollment and at a stable dose for ≥30 days before the start of study treatment were included in the study. Females of childbearing potential had to have a negative serum pregnancy test at screening. They were also required to agree to take monthly urine/serum pregnancy tests and to use reliable contraceptives to avoid pregnancy from the time of the screening visit until 30 days after the end of the study.

Eligible patients were excluded if they met any of the exclusion criteria, such as diagnosis of respiratory or cardiovascular disorder requiring immediate surgery, presence of confirmed or suspected pulmonary vein occlusion, history of myocardial infarction, and resting pulse rate of ≥120 beats/min.

Trial Drug {#Sec5}
----------

Epoprostenol AS (Actelion Pharmaceuticals Japan Ltd.) was provided in 10-mL glass vials containing 0.5 mg or 1.5 mg epoprostenol sodium. Epoprostenol AS was dissolved and diluted by adding isotonic sodium chloride solution. At the start of the 12-week treatment period, epoprostenol GM was switched to an equal dose of epoprostenol AS in the hospital. For home therapy, epoprostenol was administered via a central venous catheter by continuous drip infusion using a portable infusion pump.

Study Design {#Sec6}
------------

This was a two-site, open-label, single-arm, Phase 3b study. The study consisted of a 2-week pretreatment screening period, a 12-week open-label treatment period (visiting at baseline, week 1, 2, 4, 8, and 12), and a continuous treatment period until marketing of the study drug (visiting every 4 weeks). Pulmonary hemodynamic measurements and variables of clinical laboratory tests were collected at baseline and week 12. Medical interviews and checks for vital signs were performed at each visit. Females of childbearing potential received a pregnancy test every month.

Outcome Measures {#Sec7}
----------------

### Safety/Tolerability {#Sec8}

The safety/tolerability endpoints were adverse events occurring during the 12-week treatment phase, together with changes from baseline to week 12 for vital signs (blood pressure and heart rate on the same arm in sitting or supine position), body weight, and abnormal changes from baseline to week 12 for clinical laboratory tests (general biochemistry tests, including thyroid function test and hematology test). Vital signs and body weight were assessed at each visit and clinical laboratory tests were performed at baseline and week 12 (only thyroid function was assessed every month). Adverse events reported during the 12-week evaluation period were coded according to system organ class and terms using the Medical Dictionary for Regulatory Activities/Japanese version. The causality of adverse events in relation to the trial drug was judged by the investigators.

### Efficacy Endpoints {#Sec9}

The efficacy endpoints were changes in pulmonary hemodynamic factors, WHO functional class, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) concentrations from baseline (within 60 min before the first dose of epoprostenol AS) to immediately after switching (within 60 min after the first dose of epoprostenol AS) or week 12. Pulmonary hemodynamic factors included systolic pulmonary artery pressure, diastolic pulmonary artery pressure, mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output, mean right atrial pressure, mixed venous oxygen saturation, cardiac index, pulmonary vascular resistance, and pulmonary vascular resistance index. Pulmonary hemodynamics were measured by right heart catheterization, which was performed according to standard local procedures through the internal jugular, subclavian, or femoral vein by a balloon catheter placed into either the right or left pulmonary artery in a sterilized cardiac catheterization laboratory. Cardiac Output (CO) was measured using Fick's method \[[@CR18]\].

### Treatment Satisfaction {#Sec10}

The abbreviated nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), employed for the quality of life assessment, is a validated questionnaire that permits comparisons of patients' treatment satisfaction across medication types and patient conditions \[[@CR19]\]. The changes from baseline to week 12 in treatment satisfaction were assessed using the TSQM-9. This questionnaire includes three items for each of three domains: effectiveness, convenience, and global satisfaction. The scores for each domain range from 0 to 100, where higher scores indicate higher satisfaction on that domain.

Statistical Analysis {#Sec11}
--------------------

This study was an exploratory study. No hypothesis was set and no power considerations were made for this study. Patients who received at least one dose of the study drug were included in the all-treated set for analyses. Patients who had assessable data at baseline and week 12 were included in the analysis of pulmonary hemodynamics. All statistical analyses were considered to be exploratory and the significance level was set at 5% (two-sided). The efficacy variables were summarized descriptively by calculating the mean, standard deviation, standard error, median, 25th and 75th percentiles, minimum and maximum. Changes from baseline were examined using the Wilcoxon signed rank sum test. All analyses were performed using SAS (Version 9.2; SAS Inc., Cary, North Carolina, USA).

RESULTS {#Sec12}
=======

Patients {#Sec13}
--------

The study was conducted at two Japanese study sites, and started in October 2011. Eight Japanese patients (one male, seven females) with PAH were treated with the study drug and completed the 12-week evaluation period by October 2012. The characteristics of the patients are summarized in Table [1](#Tab1){ref-type="table"} and Supplemental Table [1](#Tab1){ref-type="table"}. The mean (range) age and time from PAH diagnosis were 47.6 (25--69) years and 6.21 (0.6--13.9) years, respectively. At baseline, seven patients had IPAH and one had HPAH. The WHO functional class was Class I for one patient, Class II for five patients, and Class III for two patients. Epoprostenol AS was started at the same dose of epoprostenol GM, with a mean (range) dose of 40.13 (17.0--61.0) ng/kg/min. The mean (range) duration of exposure to epoprostenol AS during the 12-week treatment period was 86.9 (78.4--91.6) days. There were no dose adjustments in any patient. All of the patients completed the study schedule during the evaluation period. The continuous treatment period was ongoing as of February 2013.Table 1Patient characteristicsBackground factors*N* = 8Sex, *n* (%) Male1 (12.5) Female7 (87.5)Age, years Mean ± SD47.6 ± 12.5 Median46.0 \[Min, Max\]\[25, 69\]Age in class 20--64 years7 (87.5) ≥65 years1 (12.5)Race, *n* (%) Asian8 (100.0)Body mass index, kg/m^2^ Mean ± SD19.94 ± 2.21 Median20.40 \[Min, Max\]\[15.4, 23.0\]Etiology of PAH, *n* (%) IPAH7 (87.5) HPAH1 (12.5) APAH-DT0 (0.0) APAH-CTD0 (0.0)Time since PAH diagnosis, years Mean ± SD6.21 ± 5.24 Median5.26 \[Min, Max\]\[0.6, 13.9\]WHO functional class, *n* (%) I1 (12.5) II5 (62.5) III2 (25.0) IV0 (0.0)*APAH*-*CTD* associated with pulmonary arterial hypertension-connective tissue disease, *APAH*-*DT* associated with pulmonary arterial hypertension-drugs and toxins induced, *HPAH* heritable pulmonary arterial hypertension, *IPAH* idiopathic pulmonary arterial hypertension, *PAH* pulmonary arterial hypertension, *SD* standard deviation

Safety {#Sec14}
------

Adverse events reported during the 12-week evaluation period are summarized in Table [2](#Tab2){ref-type="table"} according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities/Japanese version. Seven out of eight patients (87.5%) experienced a total of 18 adverse events. Three patients (37.5%) experienced a total of four adverse events that were considered related to the study drug. Two patients (25.0%) experienced serious adverse events: moderate pneumonia and mild device dislocation in one patient each, both of which were not considered related to the study drug. There were no deaths or adverse events leading to treatment discontinuation during the study. Seven out of eight patients (87.5%) experienced mild adverse events and three (37.5%) experienced moderate adverse events; there were no severe adverse events. The most frequent event was nausea, which was reported by two patients. The other adverse events occurred in one patient only. There were no clinically significant changes from baseline to week 12 in blood pressure, heart rate, body weight, or clinical laboratory tests.Table 2Summary of treatment-emergent adverse events by intensity and system organ classAsymptomaticMildModerateSevereTotal (*n* = 8)All system organ classes Total pts with at least one AE0 (0.0%)7 (87.5)3 (37.5%)0 (0.0%)7 (87.5%) Total number of AEs0117018Gastrointestinal disorders Total pts with at least one AE0 (0.0%)3 (37.5%)3 (37.5%)0 (0.0%)5 (62.5%) Total number of AEs03306 Nausea0 (0.0%)0 (0.0%)2 (25.0%)0 (0.0%)2 (25.0%) Diarrhea0 (0.0%)0 (0.0%)1 (12.5%)0 (0.0%)1 (12.5%) Gastritis0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%) Vomiting0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%) Mikulicz's disease0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%)Infections and infestations Total pts with at least one AE0 (0.0%)1 (12.5%)2 (25.0%)0 (0.0%)3 (37.5%) Total number of AEs01203 Pharyngitis0 (0.0%)0 (0.0%)1 (12.5%)0 (0.0%)1 (12.5%) Pneumonia0 (0.0%)0 (0.0%)1 (12.5%)0 (0.0%)1 (12.5%) Cellulitis0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%)General disorders and administrations site conditions Total pts with at least one AE0 (0.0%)2 (25.0%)0 (0.0%)0 (0.0%)2 (25.0%) Total number of AEs02002 Device dislocation0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%) Injury associated with device0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%)Skin and subcutaneous tissue disorders Total pts with at least one AE0 (0.0%)2 (25.0%)0 (0.0%)0 (0.0%)2 (25.0%) Total number of AEs03003 Dermatitis allergic0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%) Drug eruption0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%) Rash0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%)Ear and labyrinth disorders Total pts with at least one AE0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%) Total number of AEs01001 Vertigo0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%)Musculoskeletal and connective tissue disorders Total pts with at least one AE0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%) Total number of AEs01001 Arthralgia0 (0.0%)1 (12.5%)0 (0.0%)0 (0.0%)1 (12.5%)Nervous system disorders Total pts with at least one AE0 (0.0%)0 (0.0%)1 (12.5%)0 (0.0%)1 (12.5%) Total number of AEs00101 Hypoasthesia0 (0.0%)0 (0.0%)1 (12.5%)0 (0.0%)1 (12.5%)Respiratory, thoracic and mediastinal disorders Total pts with at least one AE0 (0.0%)0 (0.0%)1 (12.5%)0 (0.0%)1 (12.5%) Total number of AEs00101 Pleurisy0 (0.0%)0 (0.0%)1 (12.5%)0 (0.0%)1 (12.5%)*AE* adverse event, *pts* patients

Efficacy {#Sec15}
--------

Table [3](#Tab3){ref-type="table"} shows the hemodynamic factors measured within 60 min before (i.e., baseline) and 60 min after the first dose of epoprostenol, as well as the changes between these two times. As shown in Table [3](#Tab3){ref-type="table"}, there were no marked changes in pulmonary hemodynamic parameters from 60 min before to 60 min after the first dose of epoprostenol AS. Wilcoxon signed rank sum tests revealed no significant differences at the 5% level for the changes from baseline. Table [4](#Tab4){ref-type="table"} presents the hemodynamic factors measured at baseline and at week 12, together with their changes between these times. As shown in Table [4](#Tab4){ref-type="table"}, there were no remarkable changes in pulmonary hemodynamic factors from baseline to week 12. Additionally, Wilcoxon signed rank sum tests revealed no significant differences at the 5% level for the changes from baseline. The WHO functional class was unchanged from baseline to week 12, as one was categorized as Class I, five as Class II, and two as Class III (Table [5](#Tab5){ref-type="table"}). The mean (range) NT-proBNP concentration was 139 (57--240) pg/mL at baseline and 106 (41--243) pg/mL at week 12. The mean (range) change from baseline to week 12 was −--43.3 (−196 to 43) pg/mL, which was not clinically significant (Wilcoxon signed rank sum test: *P* = 0.5781) (Fig. [1](#Fig1){ref-type="fig"}).Table 3Changes in hemodynamic parameters from baseline to within 60 min after switching epoprostenol formulationsHemodynamic parameterBaseline (*n* = 8)After 60 min (*n* = 8)Actual valueActual valueChanges from baseline*P* value^a^Mean ± SDMedian\[Min, Max\]Mean ± SDMedian\[Min, Max\]Mean ± SDMedian\[Min, Max\]Systolic pulmonary artery pressure, mmHg50.6 ± 12.446.0\[34, 69\]50.5 ± 12.548.0\[33, 72\]−0.1 ± 4.2−0.5\[−7, 6\]0.8438Diastolic pulmonary artery pressure, mmHg17.1 ± 2.217.0\[14, 22\]16.5 ± 2.216.0\[13, 20\]−0.6 ± 1.8−0.5\[−4, 2\]0.5313Mean pulmonary artery pressure, mmHg31.1 ± 5.131.5\[22, 40\]30.4 ± 4.630.0\[22, 37\]−0.8 ± 2.2−0.5\[−4, 2\]0.4375Pulmonary capillary wedge pressure, mmHg8.4 ± 1.88.0\[5, 11\]7.1 ± 1.76.5\[5, 10\]−1.3 ± 1.3−1.5\[−3, 1\]0.0625Cardiac output, L/min4.829 ± 1.0574.440\[2.72, 5.99\]4.834 ± 1.3494.535\[3.45, 6.76\]0.545 ± 0.7820.420\[−0.31, 1.84\]0.1094Mean right arterial pressure, mmHg4.8 ± 1.84.5\[3, 8\]3.6 ± 1.53.5\[1, 6\]−1.1 ± 2.0−1.5\[−3, 3\]0.2031Mixed venous oxygen saturation, %73.43 ± 5.5073.20\[63.4, 83.2\]73.86 ± 5.8272.15\[66.0, 84.5\]0.44 ± 2.730.30\[−3.9, 3.7\]0.8438Cardiac input, L/min/m^2^2.98 ± 0.862.80\[2.0, 4.3\]3.39 ± 1.202.95\[2.2, 5.4\]0.41 ± 0.600.20\[−0.2, 1.5\]0.1250Pulmonary vascular resistance, dyn·s/cm^5^448.3 ± 158.1429.5\[201, 676\]406.0 ± 143.6380.0\[232, 680\]−42.3 ± 84.1−14.0\[−166, 41\]0.4609Pulmonary vascular resistance index, dyn·s/cm^5^/m^2^646.5 ± 223.1598.0\[338, 1,000\]594.8 ± 237.3534.5\[384, 1,091\]−51.8 ± 124.3−22.5\[−239, 91\]0.4609*SD* standard deviation^a^*P* value based upon Wilcoxon signed rank sum testTable 4Changes in hemodynamic parameters from baseline to 12 weeks after switching epoprostenol formulationsHemodynamic parameterBaseline (*n* = 8)After 60 min (*n* = 8)Actual valueActual valueChanges from baseline*P* value^a^Mean ± SDMedian\[Min, Max\]Mean ± SDMedian\[Min, Max\]Mean ± SDMedian\[Min, Max\]Systolic pulmonary artery pressure, mmHg50.6 ± 12.446.0\[34, 69\]49.8 ± 14.144.5\[29, 70\]−0.9 ± 3.5−1.0\[−5, 4\]0.4375Diastolic pulmonary artery pressure, mmHg17.1 ± 2.217.0\[14, 22\]18.8 ± 4.619.0\[11, 24\]1.6 ± 3.72.0\[−3, 7\]0.4844Mean pulmonary artery pressure, mmHg31.1 ± 5.131.5\[22, 40\]31.4 ± 7.232.0\[18, 41\]0.3 ± 2.80.5\[−4, 4\]0.8906Pulmonary capillary wedge pressure, mmHg8.4 ± 1.88.0\[5, 11\]7.3 ± 1.27.5\[6, 9\]−1.1 ± 2.3−2.0\[−4, 3\]0.2344Cardiac output, L/min4.829 ± 1.0574.440\[2.72, 5.99\]4.499 ± 1.0054.095\[3.25, 5.98\]0.210 ± 0.7900.310\[−0.91, 1.35\]0.4609Mean right arterial pressure, mmHg4.8 ± 1.84.5\[3, 8\]4.8 ± 1.84.5\[3, 7\]0.0 ± 1.70.0\[−3, 3\]1.0000Mixed venous oxygen saturation, %73.43 ± 5.5073.20\[63.4, 83.2\]72.10 ± 3.2872.75\[67.1, 76.3\]−1.33 ± 4.64−0.50\[−8.4, 4.7\]0.5469Cardiac input, L/min/m^2^2.98 ± 0.862.80\[2.0, 4.3\]3.11 ± 0.723.00\[2.4, 4.3\]0.14 ± 0.52−0.25\[−0.6, 0.9\]0.6563Pulmonary vascular resistance, dyn·s/cm^5^448.3 ± 158.1429.5\[201, 676\]453.6 ± 175.3424.5\[154, 686\]5.4 ± 78.3−25.0\[−61, 182\]0.5469Pulmonary vascular resistance index, dyn·s/cm^5^/m^2^646.5 ± 223.1598.0\[338, 1,000\]648.5 ± 239.6640.5\[251, 992\]2.4 ± 98.4−15.5\[−87, 212\]0.7109*SD* standard deviation^a^*P* value based upon Wilcoxon signed rank sum testTable 5Changes in WHO FC from baseline to week 12WHO FCBaselineWeek 12IIIIIIIV*NN*\[*N*\]\[*N*\]\[*N*\]\[*N*\]8I11------II5--5----III2----2--IV0------0*FC* functional class, *WHO* World Health OrganizationFig. 1NT-proBNP concentration measured at baseline and at week 12. *P* = 0.5781 at the 5% level (Wilcoxon signed rank sum test) *NT*-*proBNP* N-terminal prohormone of brain natriuretic peptide

Treatment Satisfaction {#Sec16}
----------------------

Table [6](#Tab6){ref-type="table"} shows the scores for all three domains of the TSQM-9 recorded at baseline and week 12, together with the changes from baseline to week 12. As shown in this table, there were improvements in all three domains during the 12-week treatment period. The improvement in convenience was statistically significant (Wilcoxon signed rank sum test: *P* = 0.0313).Table 6Changes in treatment satisfaction from baseline to 12 weeks after switching epoprostenol formulationsTSQM-9 domainBaseline (*n* = 8)12 weeks of administration (*n* = 8)Actual scaleActual scaleChanges from baselineMean ± SDMedian\[Min, Max\]Mean ± SDMedian\[Min, Max\]Mean ± SDMedian\[Min, Max\]*P* value^a^Effectiveness56.25 ± 7.5558.4\[44.4, 66.7\]58.31 ± 14.5561.1\[33.3, 72.2\]2.06 ± 10.680.0\[−11.1, 22.2\]0.9063Convenience51.40 ± 10.1955.6\[33.3, 61.1\]58.33 ± 12.9661.1\[33.3, 72.2\]6.93 ± 5.735.6\[0.0, 16.6\]0.0313Global satisfaction54.01 ± 31.3060.5\[−8.3, 91.7\]54.19 ± 25.9452.8\[22.2, 93.1\]0.18 ± 23.091.4\[−40.2, 30.5\]0.7188*SD* standard deviation, *TSQM*-9 Treatment Satisfaction Questionnaire for Medication^a^*P* value based upon Wilcoxon signed rank sum test

DISCUSSION {#Sec17}
==========

The results of this study demonstrate that patients with PAH can be switched from epoprostenol GM to a new formulation of epoprostenol sodium, epoprostenol AS, with no apparent safety concerns or deteriorations in pulmonary hemodynamic factors. Switching from epoprostenol GM to epoprostenol AS was also associated with an improvement in convenience across three treatment satisfaction domains.

The new formulation of epoprostenol is stable for 24 h at room temperature (1--30 °C) after preparation/dilution in saline, and the prepared solution does not require cooling with a frozen gel pack, which is expected to improve the quality of life of patients, particularly in terms of their daily activities. This expectation is supported by the results of the treatment satisfaction questionnaire, which showed an improvement in convenience. Therefore, patients with PAH treated with conventional formulations of epoprostenol sodium could be switched to epoprostenol AS, a stable formulation at room temperature, and may enhance their quality of life through improvements in treatment convenience.

The outdoor air temperature during the summer in many regions of Japan often exceeds 30 °C, and the temperature around the medication cassette of the diluted solution could be even higher \[[@CR20]\]. As part of the risk-management strategy in this study, patients were instructed to use a frozen gel pack during the summer, especially when the environmental temperature exceeded room temperature. In this study, two out of eight patients used a frozen gel pack during the treatment period, but neither of these patients experienced any changes in their overall condition. In addition, the earthquake and tsunami that hit eastern Japan on March 11, 2011, exposed flaws in the systems used to ensure patient safety and maintain a stable supply of medical resources during an emergency \[[@CR21]\]. If essential utilities such as electricity and water networks are shut down following a disaster, it is likely that frozen gel packs would not be available, which may be a life-threatening issue for patients with PAH. The authors speculate that epoprostenol AS, which is stable for a longer time at room temperature than the GM formulation, could be valuable for continuing medical treatment during emergencies, and may have a positive impact on the quality of medical care, although additional examination of epoprostenol AS use is required in situations where the temperature exceeds 30 °C. Further studies are needed to evaluate the impact of higher environmental temperatures on the safety/tolerability and efficacy of this formulation, and to accumulate evidence supporting its clinical use.

Some limitations of this study warrant mention. Firstly, the sample size was small, which may prevent detection of small differences in hemodynamic factors or infrequent adverse events. Secondly, as the study was conducted in an open-label manner without a control group (e.g., of patients continuing epoprostenol GM during the 12-week treatment phase), it is possible that a study effect or patient bias contributed to the observed improvements in treatment satisfaction.

CONCLUSION {#Sec18}
==========

In conclusion, the present study showed that switching to a new formulation of epoprostenol was associated with an improvement in convenience in relation to treatment satisfaction, without unexpected adverse events or deteriorations in pulmonary hemodynamic factors. Prospective studies in a larger group of patients are needed to confirm the safety of this formulation in long-term clinical use. Epoprostenol AS was approved in February 2013 in Japan as a generic drug with the same potency and effectiveness as the originally approved drug, epoprostenol GM. As intravenous epoprostenol sodium therapy may result in high medical costs, the introduction of cheaper generic drugs may help to reduce medical expenditure for treating PAH.
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